Deborah Ambrosini appointed as CFO & Company Secretary
Released
Released
Announcement PDF
ASX Announcement
PERCHERON APPOINTS DEBORAH AMBROSINI
AS CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY
Melbourne, Australia – 17 June 2024: Percheron Therapeutics Limited, an international
biotechnology company focused on the development of novel therapies for rare
diseases, is pleased to announce, in accordance with Listing Rule 3.16.1, the
appointment of Deborah Ambrosini as Chief Financial Officer and Company Secretary,
with immediate effect.
Ms Ambrosini will be responsible for communication with ASX in relation to Listing Rules
matters under Listing Rule 12.6.
“We are delighted to welcome Deborah to the Percheron team,” commented Percheron
CEO, Dr James Garner. “As we engage more actively with potential partners, and as we
begin to present the company to a much broader range of potential investors, it is timely
to bring a CFO with Deborah’s formidable experience on board. She brings a track record
of success, a rich professional network, an impressive work ethic, and a wealth of
technical experience to the company, and we look forward to working with her as we
continue to implement the strategy the Board has laid out.”
Ms Ambrosini is a highly experienced corporate executive with more than twenty years of
experience as a Chief Financial Officer in both private and ASX-listed companies. She is
a Chartered Accountant by training and began her career with PricewaterhouseCoopers.
Since then, she has helped to grow companies across a range of industries. In addition
to her accounting qualifications, she holds a Certificate in Governance Practice from the
Governance Institute of Australia. Ms Ambrosini is well versed in regulatory compliance,
contract negotiation, statutory compliance, financial reporting, financial analysis and
forecasting, and both debt and equity capital raising. Her prior experience in the
healthcare sector includes Cortical Dynamics Limited, Acrux Limited, and Cann Group
Limited.
“I am excited to join Percheron at this critical time,” commented Ms Ambrosini. “The
company is going through a rapid period of development and transformation, and I look
forward to working with the team to help drive its success. Having worked extensively in
the healthcare sector, I am passionate about the impact companies such as Percheron
can make in the lives of patients.”
With Ms Ambrosini’s appointment, Mr Phillip Hains, Partner at Acclime Group, will step
down as CFO and Company Secretary. The company will continue to work closely with
the Acclime Group team on its accounting and statutory compliance obligations.
“I want to thank Phillip Hains for his many years of support to the company,” added Dr
Garner. “He and the team at, initially, CFO Solutions and, more recently, Acclime Group
Percheron Therapeutics Limited
ABN 41 095 060 745
ASX: PER | FSE: AWY | US OTC: ATHJY
have made an enormous contribution to the company, such that it has now matured to
the stage where an in-house role makes sense.”
~ ENDS ~
About Percheron Therapeutics Limited
Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJY | FSE: AWY] is a publicly listed
biotechnology company focused on the development and commercialisation of novel therapies
for rare diseases. The company’s lead program is ATL1102, an antisense oligonucleotide
targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase
IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy
(DMD), for which data is expected in 2H CY2024. The company previously reported promising
results from an exploratory phase IIa study of in the same population and has been awarded
orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.
For more information, please contact info@PercheronTx.com.
This announcement has been authorized for release to the Australian Securities Exchange
by the Board of Directors.
Page 2 of 2
Share your feedback
Discover